Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.

This source describes the implementation of a province-wide lung cancer screening program in Ontario, emphasizing that organized, program-based low-dose CT screening for high-risk populations is seen as more effective in reducing cancer incidence and mortality, while being cost-effective compared to non-organized screenings.

This report summarizes discussions from a lung cancer awareness forum highlighting diagnostic challenges, the importance of survivorship care, and the need for ongoing research; it presents no new clinical findings.

In this review, the researchers identify and discuss promising molecular and genetic targets for lung cancer therapy, suggesting that advancements in understanding these targets could lead to new drug developments and more effective treatments.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

This review discusses the potential of natural products to induce ferroptosis as a promising therapeutic strategy for non-small cell lung cancer and reports no clinical results; the authors highlight the need for further comprehensive studies.

In this study, lung cancer patients undergoing treatment with immune checkpoint inhibitors and chemotherapy reported high incidence and severity of symptoms such as fatigue, drowsiness, and loss of appetite, which were most prominent and distressing throughout the treatment cycles.

This study used in silico analysis to identify 4-[2-(4-nitrophenyl)ethylcarbamoyl]benzenesulfonyl as a potential inhibitor of the EGFR mutant associated with NSCLC, highlighting the need for further in vitro and in vivo validation.

This study found that soy isoflavones protected normal lung structures in mice against radiation-induced inflammation, damage, and increased breathing rate following radiation treatment.

This study found that a three-month regimen of leucoselect phytosome, a grape seed extract complex, was well tolerated and significantly reduced bronchial proliferation markers in heavy active and former smokers.

This study found that non-small-cell lung cancer patients experienced less adverse events with third-generation EGFR-TKIs compared to first and second generations, although fear of cancer progression, anxiety, and depression were still prevalent.

This study demonstrated that the antiandrogen drug enzalutamide may reduce TMPRSS2 levels in human lung cells and mouse lungs, supporting its potential as a COVID-19 treatment option.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

The researchers reported that their novel formulation of pterostilbene-loaded ethoniosomes with folic acid coating effectively targeted lung cancer cells in vitro and demonstrated promising results in animal models, indicating potential for future targeted chemotherapy applications.

This study found that fucoidan significantly inhibited lung cancer cell phenotypes while sparing normal cells and altered gene expression, suggesting its potential for lung cancer therapy.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

This study found that Brazilian patients with advanced NSCLC required significant survival gains to accept treatments causing severe tiredness or skin rash, with preferences varying among treatment options.

This study used a 3D bioprinted human lung cancer model in a mouse phantom to demonstrate a selective cytotoxic effect of X-rays on tumor cells, revealing differences from 2D cell models.

This review highlights that direct drug delivery to the lungs for treating lung cancer may offer more precise targeting while reducing side effects compared to traditional methods.

This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.

This report describes a rare case of eyelash overgrowth and eyelid irritation in a woman treated with erlotinib for lung adenocarcinoma, highlighting a potential side effect of the drug.

This paper reviews research on the link between small cell lung cancer and metabolic syndrome, highlighting that existing studies indicate metabolic syndrome may contribute to lung cancer development through mechanisms like insulin resistance, chronic inflammation, and oxidative stress.

Flubendazole in a nanoemulsion can potentially treat lung cancer and cryptococcal meningitis effectively and safely.

This article explores gender differences in lung cancer, noting a higher number of nonsmoking women over age 60 with lung cancer compared to men, and highlights potential hormonal and molecular influences; no new study results were presented.

This study observed that frontal plus moderate vertex baldness at age 45 was associated with a higher risk of aggressive prostate cancer in a large cohort.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.